MFG
AKBA icon

Magnus Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Magnus Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,000
Closed -$2.85K – 245
2021
Q2 		$4K Buy
+1,000
New +$3.37K ﹤0.01% 245
2020
Q4 		– Sell
-4,000
Closed -$11.7K – 357
2020
Q3 		$10K Buy
+4,000
New +$35.1K ﹤0.01% 314

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Magnus Financial Group's AKBA Position: Q3 2021 in Review

Magnus Financial Group sold out of Akebia Therapeutics (AKBA) in Q3 2021, closing a stake of 1,000 shares — an estimated $2.85K sold.

Magnus Financial Group first reported a position in AKBA in Q3 2020 and held it in 2 quarters. The position peaked at $10K in Q3 2020. 126 funds tracked by Wall St. Rank hold AKBA as of Q3 2021.

  • Magnus Financial Group reported no remaining Akebia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Magnus Financial Group sold 1,000 Akebia Therapeutics shares in Q3 2021, an estimated $2.85K.
  • Magnus Financial Group first reported a position in Akebia Therapeutics in Q3 2020 and held it in 2 quarters.
  • Magnus Financial Group's Akebia Therapeutics position peaked at $10K in Q3 2020.
  • 126 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2021.

Based on Magnus Financial Group's 13F filing for Q3 2021, filed 12 Nov 2021.